NPI: 1396857488 · LIVINGSTON, NJ 07039 · General Acute Care Hospital · NPI assigned 08/31/2006
Authorized official DAVIS, RICHARD controls 20+ related entities in our dataset. Read more
| Authorized Official | DAVIS, RICHARD (PRESIDENT/CEO) |
| Parent Organization | RWJ BARNABAS HEALTH INC |
| NPI Enumeration Date | 08/31/2006 |
Other providers sharing the same authorized official: DAVIS, RICHARD
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 239,208 | $19.72M |
| 2019 | 248,376 | $18.59M |
| 2020 | 191,975 | $13.25M |
| 2021 | 249,620 | $18.62M |
| 2022 | 353,918 | $20.38M |
| 2023 | 402,914 | $24.83M |
| 2024 | 313,420 | $21.41M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 68,486 | 64,802 | $25.40M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 45,204 | 42,454 | $20.49M |
| G0378 | Hospital observation service, per hour | 21,709 | 19,156 | $18.41M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 34,725 | 31,189 | $14.66M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5,747 | 5,421 | $4.14M |
| OP250 | 121,944 | 89,555 | $4.04M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14,929 | 14,237 | $3.32M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 9,321 | 5,574 | $3.03M |
| J2350 | Injection, ocrelizumab, 1 mg | 130 | 99 | $2.19M |
| 80053 | Comprehensive metabolic panel | 115,674 | 87,478 | $2.18M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 776 | 755 | $1.71M |
| 96375 | Therapeutic injection; each additional sequential IV push | 24,631 | 18,775 | $1.23M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 34,036 | 9,191 | $1.13M |
| 93017 | 2,969 | 2,666 | $1.13M | |
| 71046 | Radiologic examination, chest; 2 views | 21,932 | 20,922 | $1.12M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 7,552 | 4,861 | $993K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3,698 | 1,754 | $977K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 295 | 291 | $885K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 25,383 | 6,772 | $787K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2,288 | 2,100 | $768K |
| OP370 | 9,914 | 8,932 | $767K | |
| 96415 | 2,381 | 1,717 | $734K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 24,242 | 20,913 | $732K |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 256 | 181 | $716K |
| J2323 | Injection, natalizumab, 1 mg | 187 | 153 | $686K |
| 36415 | Collection of venous blood by venipuncture | 140,300 | 97,191 | $685K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 34,773 | 30,836 | $590K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7,359 | 2,075 | $588K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 110,072 | 83,336 | $579K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 14,254 | 6,371 | $575K |
| 93970 | 2,213 | 2,059 | $539K | |
| OP272 | 13,353 | 11,352 | $531K | |
| 71045 | Radiologic examination, chest; single view | 11,401 | 10,196 | $525K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 26,554 | 24,635 | $521K |
| OP710 | 10,305 | 9,332 | $502K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4,434 | 4,202 | $493K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 639 | 531 | $480K |
| C1776 | Joint device (implantable) | 236 | 162 | $433K |
| 93458 | 337 | 279 | $427K | |
| 96417 | 2,069 | 1,182 | $417K | |
| 30140 | 229 | 226 | $409K | |
| 70450 | Computed tomography, head or brain; without contrast material | 7,848 | 7,186 | $374K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 29,390 | 26,698 | $362K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4,387 | 4,194 | $359K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 9,207 | 8,589 | $329K |
| 93971 | 1,973 | 1,858 | $320K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 7,878 | 5,841 | $314K |
| OP258 | 45,262 | 34,364 | $310K | |
| 96367 | 2,475 | 1,718 | $307K | |
| 81001 | 53,913 | 43,833 | $245K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 12,356 | 9,578 | $243K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3,221 | 2,998 | $240K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 8,191 | 7,527 | $235K |
| 86850 | 14,757 | 12,839 | $233K | |
| J9271 | Injection, pembrolizumab, 1 mg | 38 | 26 | $225K |
| 92587 | 1,199 | 1,177 | $221K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4,892 | 4,109 | $220K |
| 97802 | 1,105 | 1,043 | $202K | |
| 76770 | 1,703 | 1,667 | $199K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2,386 | 2,295 | $198K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2,279 | 2,195 | $195K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18,005 | 11,937 | $181K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 5,529 | 2,083 | $174K |
| 77336 | 1,150 | 469 | $172K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1,674 | 856 | $163K |
| 80197 | 17,209 | 9,264 | $163K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4,268 | 3,894 | $162K |
| OP270 | 4,650 | 4,205 | $160K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 2,655 | 2,348 | $158K |
| 77334 | 279 | 192 | $154K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2,509 | 2,244 | $154K |
| 85027 | 19,356 | 13,971 | $149K | |
| J2505 | Injection, pegfilgrastim, 6 mg | 34 | 24 | $149K |
| 97014 | 3,568 | 1,086 | $147K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 10,965 | 8,064 | $146K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4,214 | 4,072 | $142K |
| 92567 | 1,864 | 1,805 | $140K | |
| 73564 | 3,326 | 2,994 | $140K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1,399 | 1,326 | $137K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 202 | 199 | $132K |
| 73630 | 3,180 | 2,971 | $132K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4,325 | 3,996 | $130K |
| 87081 | 4,642 | 4,597 | $128K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 2,265 | 1,952 | $124K |
| J0897 | Injection, denosumab, 1 mg | 79 | 72 | $124K |
| 74021 | 3,161 | 3,025 | $122K | |
| 73030 | 2,111 | 1,936 | $119K | |
| G0379 | Direct admission of patient for hospital observation care | 2,424 | 2,119 | $118K |
| 83735 | 27,104 | 16,736 | $117K | |
| 86900 | 16,541 | 14,616 | $117K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,867 | 2,547 | $113K |
| 80061 | Lipid panel | 8,067 | 7,135 | $107K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1,322 | 1,277 | $107K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5,239 | 5,183 | $106K |
| 96411 | 325 | 185 | $104K | |
| 95816 | 402 | 357 | $102K | |
| 97161 | 3,080 | 2,910 | $101K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 17,848 | 15,645 | $101K |
| 97803 | 625 | 573 | $97K | |
| 82962 | 11,467 | 8,221 | $96K | |
| 82043 | 3,126 | 2,790 | $96K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4,939 | 4,398 | $95K |
| 85610 | 18,103 | 14,416 | $94K | |
| 87799 | 6,209 | 4,830 | $92K | |
| 76830 | Ultrasound, transvaginal | 1,623 | 1,561 | $92K |
| 73130 | 2,144 | 2,011 | $89K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1,458 | 1,385 | $88K |
| 94729 | 673 | 567 | $87K | |
| J1756 | Injection, iron sucrose, 1 mg | 2,378 | 969 | $86K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 460 | 426 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | 8,134 | 7,207 | $81K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 3,006 | 2,215 | $79K |
| 73610 | 2,788 | 2,607 | $78K | |
| 97535 | Self-care/home management training, each 15 minutes | 3,124 | 2,088 | $78K |
| 83970 | 2,766 | 2,344 | $76K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 1,528 | 1,369 | $75K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 412 | 385 | $74K |
| 74018 | 1,947 | 1,861 | $74K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3,169 | 2,802 | $74K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5,544 | 4,246 | $72K |
| 87631 | 3,122 | 2,938 | $72K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 11,411 | 8,929 | $69K |
| 94060 | 314 | 293 | $69K | |
| 82378 | 3,203 | 2,494 | $68K | |
| 72100 | 1,909 | 1,784 | $66K | |
| 84100 | 22,273 | 13,537 | $66K | |
| 96401 | 460 | 353 | $65K | |
| 86803 | 14,288 | 13,552 | $64K | |
| 92557 | 437 | 412 | $64K | |
| 82803 | 3,057 | 2,704 | $63K | |
| 86901 | 16,628 | 14,596 | $62K | |
| OP278 | 129 | 104 | $62K | |
| 36430 | 600 | 415 | $62K | |
| 85730 | 12,849 | 11,442 | $59K | |
| 16020 | 1,050 | 813 | $58K | |
| 73110 | 1,349 | 1,272 | $57K | |
| 87070 | 4,032 | 3,774 | $57K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 602 | 487 | $57K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 91 | 59 | $57K |
| A9270 | Non-covered item or service | 14,898 | 9,985 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | 9,408 | 8,371 | $52K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3,293 | 3,091 | $52K |
| 82542 | 1,958 | 1,915 | $52K | |
| 87040 | 4,437 | 3,979 | $52K | |
| J2785 | Injection, regadenoson, 0.1 mg | 1,056 | 905 | $52K |
| 86300 | 1,605 | 1,263 | $51K | |
| 97162 | 1,798 | 1,678 | $51K | |
| 84550 | 15,144 | 9,918 | $51K | |
| 80047 | 5,069 | 4,508 | $47K | |
| 82728 | 3,946 | 3,363 | $46K | |
| 84156 | 8,701 | 7,058 | $43K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,138 | 1,800 | $42K |
| 96402 | 560 | 459 | $42K | |
| 76801 | 474 | 408 | $41K | |
| 83615 | 13,781 | 8,427 | $41K | |
| 92552 | 439 | 433 | $41K | |
| 84702 | 5,782 | 4,628 | $39K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5,423 | 5,355 | $39K |
| 81003 | 12,620 | 11,123 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3,901 | 3,761 | $39K |
| 81025 | 6,680 | 5,866 | $36K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 491 | 378 | $34K |
| 73590 | 785 | 698 | $34K | |
| 74022 | 466 | 423 | $34K | |
| 83880 | 4,342 | 3,692 | $33K | |
| 84484 | 11,023 | 9,490 | $32K | |
| 30520 | 28 | 27 | $32K | |
| 99215 | Prolong outpt/office vis | 227 | 201 | $32K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 28 | 13 | $31K |
| 77290 | 56 | 51 | $30K | |
| 88342 | 1,870 | 1,705 | $29K | |
| 96416 | 110 | 52 | $29K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 8,199 | 6,720 | $29K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 2,284 | 1,435 | $27K |
| 87186 | 3,171 | 2,732 | $27K | |
| 76775 | 240 | 233 | $26K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 503 | 426 | $24K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 6,901 | 6,061 | $24K |
| 73502 | 1,237 | 1,085 | $24K | |
| 96376 | 2,848 | 2,187 | $24K | |
| J2704 | Injection, propofol, 10 mg | 6,930 | 6,009 | $24K |
| C1769 | Guide wire | 1,906 | 1,569 | $23K |
| 84439 | 2,485 | 2,193 | $23K | |
| 83550 | 3,316 | 2,893 | $23K | |
| J3535 | Drug administered through a metered dose inhaler | 539 | 423 | $22K |
| 87340 | 7,322 | 6,891 | $22K | |
| 83690 | 17,819 | 16,289 | $22K | |
| 82570 | 6,628 | 5,324 | $20K | |
| 83540 | 3,774 | 3,263 | $20K | |
| 73140 | 571 | 551 | $20K | |
| 77300 | 87 | 75 | $20K | |
| 94760 | 388 | 342 | $19K | |
| 72040 | 449 | 417 | $18K | |
| 82607 | 2,383 | 2,161 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 368 | 360 | $18K |
| 10060 | 431 | 390 | $17K | |
| 85007 | 5,833 | 4,819 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2,561 | 2,286 | $17K |
| 87088 | 5,224 | 4,795 | $17K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 4,585 | 3,938 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 923 | 792 | $16K |
| 87497 | 822 | 544 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 348 | 338 | $16K |
| 83605 | 3,558 | 3,164 | $16K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 369 | 363 | $16K |
| 12011 | 352 | 322 | $15K | |
| G0008 | Administration of influenza virus vaccine | 1,407 | 1,317 | $15K |
| 71250 | 125 | 113 | $15K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 36 | 12 | $15K |
| 92579 | 66 | 66 | $14K | |
| J1644 | Injection, heparin sodium, per 1000 units | 2,371 | 1,366 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 13,386 | 11,366 | $14K |
| 97165 | 515 | 457 | $14K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 347 | 248 | $13K |
| 50200 | 14 | 14 | $13K | |
| 86140 | 6,462 | 5,523 | $13K | |
| 92555 | 113 | 112 | $13K | |
| 97116 | 985 | 476 | $13K | |
| 70486 | 225 | 215 | $12K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 4,757 | 3,846 | $12K |
| 88304 | 1,361 | 1,298 | $12K | |
| 87077 | 2,011 | 1,875 | $12K | |
| 29125 | 405 | 384 | $12K | |
| 85055 | 853 | 601 | $12K | |
| 82784 | 241 | 198 | $11K | |
| 82746 | 1,619 | 1,455 | $11K | |
| 94727 | 162 | 135 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 1,075 | 909 | $11K |
| 73562 | 266 | 242 | $10K | |
| 87807 | 1,332 | 1,316 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 972 | 959 | $10K |
| 29581 | 336 | 104 | $10K | |
| 93880 | 27 | 27 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 17,002 | 15,157 | $10K |
| 73080 | 502 | 475 | $10K | |
| 83655 | 300 | 287 | $10K | |
| 74019 | 219 | 203 | $9K | |
| J1453 | Injection, fosaprepitant, 1 mg | 230 | 124 | $9K |
| 85014 | 7,289 | 6,479 | $9K | |
| 85651 | 3,699 | 3,079 | $9K | |
| 12001 | 265 | 244 | $9K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 67 | 64 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | 2,384 | 1,667 | $9K |
| 86920 | 295 | 246 | $8K | |
| 87147 | 831 | 822 | $8K | |
| 88307 | 234 | 198 | $8K | |
| 87522 | Neg quan hep c or qual rna | 794 | 607 | $8K |
| 95800 | 12 | 12 | $8K | |
| 85378 | 3,415 | 3,210 | $8K | |
| 76870 | 115 | 105 | $8K | |
| 84480 | 826 | 614 | $8K | |
| 84145 | 1,007 | 893 | $8K | |
| 87999 | 38 | 37 | $8K | |
| 87430 | 239 | 238 | $7K | |
| 93923 | 14 | 14 | $7K | |
| 87486 | 966 | 956 | $7K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 1,191 | 968 | $7K |
| 96368 | 195 | 105 | $7K | |
| 87641 | 738 | 561 | $7K | |
| 90677 | 449 | 444 | $7K | |
| 86706 | 952 | 790 | $7K | |
| 90715 | 1,630 | 1,536 | $6K | |
| 85045 | 2,250 | 1,969 | $6K | |
| 97597 | 54 | 41 | $6K | |
| 87205 | 2,694 | 2,405 | $6K | |
| 90686 | 1,216 | 1,142 | $6K | |
| 86592 | 1,686 | 1,538 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 79 | 76 | $6K |
| 73090 | 185 | 171 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 115 | 91 | $5K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 286 | 266 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2,094 | 1,752 | $5K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 789 | 775 | $5K |
| 90791 | Psychiatric diagnostic evaluation | 270 | 256 | $5K |
| 87581 | 968 | 958 | $5K | |
| 84134 | 967 | 774 | $5K | |
| 82248 | 615 | 512 | $5K | |
| 82553 | 2,196 | 1,971 | $5K | |
| 92523 | 56 | 54 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 4,429 | 4,035 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,652 | 3,259 | $4K |
| 0001A | 127 | 127 | $4K | |
| 80074 | 254 | 223 | $4K | |
| 82550 | 2,628 | 2,348 | $4K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 31 | 27 | $4K |
| 77280 | 32 | 28 | $4K | |
| 82652 | 129 | 107 | $4K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 1,495 | 557 | $4K |
| 82950 | 211 | 184 | $4K | |
| 87536 | 206 | 149 | $4K | |
| 82150 | 2,030 | 1,861 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 99 | 99 | $4K |
| 93975 | 14 | 14 | $3K | |
| G0009 | Administration of pneumococcal vaccine | 528 | 524 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 2,965 | 2,646 | $3K |
| 0002A | 111 | 111 | $3K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 12 | 12 | $3K |
| 84436 | 666 | 535 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 261 | 251 | $3K |
| 82947 | 1,645 | 1,467 | $3K | |
| 80164 | 693 | 591 | $3K | |
| 87075 | 323 | 261 | $3K | |
| 83521 | 106 | 81 | $3K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 504 | 392 | $3K |
| J1815 | Injection, insulin, per 5 units | 1,029 | 757 | $3K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 32 | 26 | $3K |
| 97022 | 220 | 62 | $3K | |
| 86334 | 172 | 141 | $3K | |
| 95951 | 35 | 13 | $3K | |
| 86336 | 108 | 104 | $3K | |
| 82985 | 443 | 356 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | 722 | 617 | $3K |
| 88300 | 75 | 64 | $3K | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | 89 | 62 | $3K |
| Q0247 | Injection, sotrovimab, 500 mg | 24 | 21 | $3K |
| 85652 | 1,149 | 980 | $2K | |
| 15853 | 97 | 89 | $2K | |
| 88311 | 301 | 297 | $2K | |
| 84165 | 396 | 290 | $2K | |
| 36416 | 810 | 554 | $2K | |
| 83883 | 210 | 140 | $2K | |
| 90670 | 32 | 32 | $2K | |
| 73552 | 57 | 49 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 55 | 55 | $2K |
| 90381 | 17 | 16 | $2K | |
| 85379 | 675 | 633 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | 168 | 88 | $2K |
| 36591 | 159 | 118 | $2K | |
| 82330 | 418 | 391 | $2K | |
| 83021 | 101 | 90 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 116 | 56 | $2K |
| 76776 | 32 | 30 | $2K | |
| 80320 | 934 | 885 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 175 | 148 | $2K |
| 84153 | 107 | 86 | $2K | |
| 80348 | 57 | 53 | $1K | |
| 99205 | Prolong outpt/office vis | 12 | 12 | $1K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 37 | 33 | $1K |
| 80179 | 407 | 362 | $1K | |
| 80177 | 369 | 307 | $1K | |
| 86038 | 233 | 217 | $1K | |
| 87517 | 147 | 106 | $1K | |
| OP637 | 1,431 | 974 | $1K | |
| C1760 | Closure device, vascular (implantable/insertable) | 30 | 25 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | 82 | 81 | $1K |
| 86160 | 45 | 38 | $1K | |
| 84703 | 187 | 181 | $1K | |
| 82247 | 79 | 61 | $1K | |
| 80358 | 57 | 53 | $1K | |
| 88313 | 50 | 39 | $1K | |
| 92522 | 13 | 13 | $1K | |
| Q3014 | Telehealth originating site facility fee | 238 | 212 | $1K |
| 29505 | 36 | 36 | $974.33 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 292 | 226 | $910.71 |
| 29515 | 39 | 37 | $894.24 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 14 | 12 | $830.46 |
| 84132 | 1,280 | 1,111 | $825.71 | |
| 84520 | 1,607 | 1,421 | $814.23 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 21 | 12 | $785.44 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 217 | 193 | $778.74 |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 29 | 27 | $767.18 |
| 80051 | 368 | 312 | $751.93 | |
| 95700 | 27 | 24 | $735.94 | |
| 86762 | 126 | 111 | $721.68 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 687 | 575 | $681.82 |
| 96523 | 15 | 12 | $681.52 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 1,297 | 757 | $676.89 |
| OP229 | 13 | 13 | $667.29 | |
| 82465 | 163 | 154 | $658.30 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | 72 | 72 | $600.56 |
| 81401 | 26 | 26 | $598.00 | |
| 84295 | 1,171 | 1,014 | $592.15 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 45 | 40 | $585.79 |
| 90651 | 57 | 56 | $584.28 | |
| 80143 | 136 | 123 | $572.60 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 194 | 120 | $547.38 |
| 82565 | 380 | 326 | $519.90 | |
| 85008 | 1,750 | 1,613 | $512.47 | |
| 82610 | 32 | 27 | $504.35 | |
| 99201 | 13 | 13 | $488.06 | |
| 84481 | 120 | 106 | $485.71 | |
| 0031A | 32 | 31 | $479.67 | |
| 86704 | 71 | 52 | $465.61 | |
| 86304 | 97 | 51 | $465.59 | |
| 85018 | 214 | 201 | $465.52 | |
| 86308 | 530 | 517 | $452.62 | |
| 88142 | 12 | 12 | $431.10 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 72 | 57 | $422.21 |
| 72170 | 45 | 37 | $417.90 | |
| 87493 | 92 | 76 | $404.67 | |
| 97164 | 12 | 12 | $364.52 | |
| 86769 | 12 | 12 | $349.86 | |
| 86617 | 24 | 24 | $341.43 | |
| 86790 | 27 | 26 | $322.18 | |
| 12002 | 16 | 13 | $320.50 | |
| 29130 | 34 | 28 | $313.32 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 426 | 319 | $303.35 |
| 89230 | 12 | 12 | $294.79 | |
| 82435 | 1,029 | 912 | $270.48 | |
| 86301 | 32 | 26 | $263.95 | |
| 73560 | 12 | 12 | $258.13 | |
| 80329 | 66 | 62 | $256.68 | |
| 82951 | 95 | 94 | $252.56 | |
| 82670 | 14 | 13 | $237.25 | |
| J3480 | Injection, potassium chloride, per 2 meq | 117 | 81 | $235.44 |
| 80076 | 103 | 89 | $217.15 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 60 | 24 | $211.37 |
| 82232 | 15 | 12 | $204.24 | |
| 74420 | 17 | 13 | $178.62 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 448 | 401 | $169.99 |
| 77012 | 30 | 24 | $156.76 | |
| 87045 | 27 | 26 | $154.04 | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | 20 | 18 | $130.00 |
| 88112 | 72 | 53 | $122.46 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 18 | 18 | $120.30 |
| 88341 | 13 | 13 | $116.02 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 615 | 552 | $115.77 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 88 | 59 | $113.91 |
| 87046 | 14 | 14 | $113.42 | |
| J9045 | Injection, carboplatin, 50 mg | 28 | 13 | $110.04 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 15 | 13 | $108.90 |
| J1940 | Injection, furosemide, up to 20 mg | 167 | 98 | $107.47 |
| 85041 | 129 | 124 | $103.20 | |
| 90656 | 61 | 61 | $102.94 | |
| 90716 | 183 | 176 | $84.62 | |
| 80158 | 25 | 12 | $80.20 | |
| 87640 | 534 | 398 | $72.76 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 279 | 251 | $71.96 |
| J1171 | Injection, hydromorphone, 0.1 mg | 122 | 85 | $69.80 |
| OP255 | 543 | 443 | $68.63 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 74 | 64 | $64.34 |
| 87899 | 15 | 15 | $61.07 | |
| 88348 | 12 | 12 | $59.71 | |
| 90681 | 195 | 185 | $58.66 | |
| 88329 | 25 | 25 | $57.86 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 170 | 153 | $57.17 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 52 | 26 | $54.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 881 | 851 | $54.80 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 129 | 94 | $53.31 |
| 85347 | 19 | 12 | $49.44 | |
| 87427 | 14 | 14 | $45.80 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 68 | 55 | $44.86 |
| 75571 | 13 | 13 | $43.42 | |
| 87206 | 12 | 12 | $39.56 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 80 | 61 | $34.05 |
| 90648 | 408 | 384 | $31.70 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 129 | 107 | $29.33 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 346 | 272 | $29.12 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 23 | 23 | $26.00 |
| J7510 | Prednisolone oral, per 5 mg | 146 | 131 | $25.73 |
| 87102 | 32 | 26 | $24.00 | |
| 82010 | 33 | 26 | $22.29 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 175 | 136 | $21.63 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 317 | 273 | $21.28 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 38 | 30 | $20.39 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 90 | 90 | $19.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 19 | 12 | $15.30 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 6,864 | 3,854 | $14.14 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 31 | 26 | $13.36 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 17 | 16 | $12.18 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 273 | 268 | $12.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 57 | 57 | $12.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 268 | 263 | $12.00 |
| 90633 | 231 | 216 | $10.98 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 16 | 13 | $8.66 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 32 | 30 | $7.66 |
| C1758 | Catheter, ureteral | 84 | 57 | $7.15 |
| Q0222 | Injection, bebtelovimab, 175 mg | 32 | 26 | $6.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 19 | 14 | $4.78 |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | 52 | 31 | $4.00 |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg | 16 | 14 | $2.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 38 | 33 | $2.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 27 | 12 | $1.63 |
| 90723 | 316 | 297 | $0.00 | |
| 90696 | 30 | 29 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 13 | 13 | $0.00 |
| 87116 | 15 | 13 | $0.00 | |
| 90697 | 21 | 21 | $0.00 | |
| 90707 | 184 | 176 | $0.00 | |
| 90734 | 13 | 13 | $0.00 | |
| 91300 | 238 | 191 | $0.00 | |
| 86618 | 13 | 13 | $0.00 | |
| 90700 | 47 | 46 | $0.00 |